Original Article
Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma
N Engl J Med 1997; 337:888-896September 25, 1997
- Abstract
Background
To detect recurrent disease in patients who have had differentiated thyroid cancer, periodic withdrawal of thyroid hormone therapy may be required to raise serum thyrotropin concentrations to stimulate thyroid tissue so that radioiodine (iodine-131) scanning can be performed. However, withdrawal of thyroid hormone therapy causes hypothyroidism. Administration of recombinant human thyrotropin stimulates thyroid tissue without requiring the discontinuation of thyroid hormone therapy.
Methods
One hundred twenty-seven patients with thyroid cancer underwent whole-body radioiodine scanning by two techniques: first after receiving two doses of thyrotropin while thyroid hormone therapy was continued, and second after the withdrawal of thyroid hormone therapy. The scans were evaluated by reviewers unaware of the conditions of scanning. The serum thyroglobulin concentrations and the prevalence of symptoms of hypothyroidism and mood disorders were also determined.
Results
Sixty-two of the 127 patients had positive whole-body radioiodine scans by one or both techniques. The scans obtained after stimulation with thyrotropin were equivalent to the scans obtained after withdrawal of thyroid hormone in 41 of these patients (66 percent), superior in 3 (5 percent), and inferior in 18 (29 percent). When the 65 patients with concordant negative scans were included, the two scans were equivalent in 106 patients (83 percent). Eight patients (13 percent of those with at least one positive scan) were treated with radioiodine on the basis of superior scans done after withdrawal of thyroid hormone. Serum thyroglobulin concentrations increased in 15 of 35 tested patients: 14 after withdrawal of thyroid hormone and 13 after administration of thyrotropin. Patients had more symptoms of hypothyroidism (P<0.001) and dysphoric mood states (P<0.001) after withdrawal of thyroid hormone than after administration of thyrotropin.
Conclusions
Thyrotropin stimulates radioiodine uptake for scanning in patients with thyroid cancer, but the sensitivity of scanning after the administration of thyrotropin is less than that after the withdrawal of thyroid hormone. Thyrotropin scanning is associated with fewer symptoms and dysphoric mood states.
Media in This Article
Figure 1
The Study Design.Figure 2
Radioiodine Scans in Patients with Thyroid Cancer after Administration of Thyrotropin and after Withdrawal of Thyroid Hormone Therapy.Article Activity
- Article
Thyroid carcinoma is diagnosed in 14,000 people each year in the United States.1 Most are effectively treated by surgery, followed often by radioiodine therapy and always by thyroid hormone therapy to suppress the secretion of thyrotropin. These patients require monitoring for recurrence of tumor, which can occur decades later.2,3 In some patients, monitoring includes periodic discontinuation of thyroid hormone therapy for radioiodine scanning 4,5 and measurement of serum thyroglobulin6,7 to detect residual or recurrent thyroid carcinoma. As a consequence of discontinuing thyroid hormone therapy, patients typically have symptomatic hypothyroidism, some may not have a sufficient increase in thyrotropin secretion for optimal imaging,8 and a few patients have accelerated tumor growth.9-11
A solution to these problems is the administration of thyrotropin to stimulate remaining thyroid tissue.12,13 Recombinant human thyrotropin has the properties and actions of native thyrotropin.14-17 In a preliminary study, thyrotropin stimulated the uptake of radioiodine by residual thyroid and thyroid-cancer tissue in patients who had previously been operated on for thyroid carcinoma.18 The current study was designed to assess the efficacy and side effects of the administration of thyrotropin as compared with the withdrawal of thyroid hormone therapy in a larger group of patients with previously treated thyroid carcinoma.
Methods
Study Patients
The subjects were 152 patients (mean age, 44 years; range, 20 to 84) with differentiated thyroid cancer for whom radioiodine scanning was indicated according to their treating physicians. The patients gave written informed consent to participate in the study, which was approved by the institutional review committee at each center. All but one patient had undergone total or subtotal thyroidectomy, and most had received radioiodine therapy. None had received drugs or radiographic contrast agents that interfere with the uptake of iodine by thyroid tissue. Twenty-five patients did not complete the study or were excluded: 14 because of protocol deviations, 4 because of adverse reactions, 4 for personal reasons, and 3 because of the inability of the independent reviewers who evaluated the radionuclide images to reach consensus. Consequently, the findings in the remaining 127 patients make up the final results of the study.
Recombinant Thyrotropin
Recombinant thyrotropin (Thyrogen, Genzyme, Cambridge, Mass.) was produced as previously described.14,19 Its biologic potency was 10 U per milligram of protein (Second World Health Organization International Reference Preparation, thyrotropin, Human, for Bioassay, 84/703).
Study Design
Two whole-body scans with iodine-131 were obtained in each patient, and the uptake of radioiodine was measured quantitatively in foci of activity thought to be normal thyroid tissue or thyroid carcinoma. The first scan was performed after administration of thyrotropin while the patient continued thyroid hormone therapy, and the second was performed after withdrawal of thyroid hormone therapy (Figure 1Figure 1
The Study Design.). Thyroid hormone treatment consisted of thyroxine in 97 patients, triiodothyronine in 6 patients, and both in 49 patients, in doses sufficient to reduce serum thyrotropin concentrations to less than 0.5 mU per liter. Thyrotropin was given intramuscularly at a dose of 0.9 mg once a day for two days. Twenty-four hours after the second dose, each patient was given 2 to 4 mCi (74 to 148 MBq) of iodine-131 orally. The first whole-body scan was obtained 48 hours later. Thyroid hormone therapy was continued for at least two weeks, and was then discontinued for at least two weeks until the serum thyrotropin concentration was greater than 25 mU per liter. The patient was then given a quantity of iodine-131 within 20 percent of that previously administered, and whole-body scanning was performed again 48 hours later.Interpretation of Radioiodine Scans and Measurement of Uptake
The radioiodine scans were evaluated by three reviewers who were not aware of the identity of the patient, the center, or the sequence of the scans. The reviewers initially categorized the technical quality of the scans, identified physiologic and abnormal sites of activity and potential artifacts, and stratified the apparent extent of disease on the basis of the presence of uptake in the thyroid bed or abnormal activity elsewhere in the neck, the lungs or mediastinum, or other distant sites. The numbers and locations of the foci of uptake were compared within each pair of scans to classify the two scans as concordant or discordant. If a pair of scans was discordant, the scan with the greater number of foci or the more widespread distribution of foci was considered superior. In 55 patients, the fractional radioiodine uptake in cervical foci was determined with a thyroid probe, by computerized region-of-interest analysis with a digital gamma camera, or both.
Other Measurements
Before each scan was obtained, the patient's vital signs; serum cholesterol, triglyceride, uric acid, creatinine, thyrotropin, and thyroglobulin concentrations; and urinary iodine20 and creatinine concentrations were measured. In 35 patients, serum samples were obtained for thyroglobulin assay before and 48, 72, and 96 hours after the administration of thyrotropin and on the day of radioiodine administration after withdrawal of thyroid hormone therapy when the serum thyrotropin concentration was at least 25 mU per liter. Serum thyrotropin was measured by an immunoassay with a sensitivity of 0.1 mU per liter. Serum thyroglobulin was measured by a radioimmunoassay (Kronus, San Clemente, Calif.) with a sensitivity of 1 μg per liter. Antithyroglobulin antibodies were also measured by radioimmunoassay (Thymune-T, Murex Diagnostics, Dartford, United Kingdom); samples with values greater than 1 U per milliliter were not analyzed for thyroglobulin. Serum samples obtained one week after the second scanning were tested for antithyrotropin antibodies.
Each patient's clinical status was assessed by the Billewicz Scale and the short-form Profile of Mood States on entry to the study and each time that radioiodine was administered. The Billewicz Scale is an observer-rated evaluation of 14 symptoms and signs of hypothyroidism.21 The short-form Profile of Mood States is a self-administered assessment of six mood states (fatigue–inertia, depression–dejection, vigor–activity, confusion–bewilderment, tension–anxiety, and anger–hostility).22
Statistical Analysis
The numbers of superior scans obtained by the two techniques were compared by the McNemar chi-square test. The differences in prescanning serum thyrotropin concentrations, absolute and fractional uptake of radioiodine, and prevalences of symptoms and disordered mood states, as assessed by the Billewicz Scale and the Profile of Mood States, were analyzed by the Wilcoxon signed-rank test. All statistical tests were two-sided.
Results
The characteristics of the 127 patients who completed the study are shown in Table 1Table 1
Characteristics of 127 Patients with Thyroid Carcinoma..Serum Thyrotropin Concentrations
The mean (±SD) serum thyrotropin concentrations rose from a base line of 0.2±0.3 mU per liter to 101±60 and 132±89 mU per liter 24 hours after the first and second doses of thyrotropin, respectively. Seventy-two hours after the second dose of thyrotropin, the mean serum thyrotropin concentration was 16±12 mU per liter. In comparison, the mean serum thyrotropin concentration on the day of radioiodine administration after withdrawal of thyroid hormone was 101±77 mU per liter.
Whole-Body Radioiodine Scanning after Thyrotropin Administration and after Thyroid Hormone Withdrawal
In 65 patients (51 percent), both the scan obtained after administration of thyrotropin and the scan obtained after withdrawal of thyroid hormone were negative. Among the 62 patients who had a positive scan with one or both techniques, 45 had radioiodine uptake limited to the thyroid bed, 10 had cervical activity consistent with local metastases, 4 had apparent intrathoracic metastases, 2 had skeletal or hepatic metastases, and 1 had activity interpreted as intrathoracic by one reviewer and as cervical by another.
The two scans were equivalent in 41 of the 62 patients (66 percent) who had at least one positive scan (Figure 2AFigure 2
Radioiodine Scans in Patients with Thyroid Cancer after Administration of Thyrotropin and after Withdrawal of Thyroid Hormone Therapy., Figure 2B, Figure 2C, Figure 2D, Figure 2E, Figure 2F, Figure 2G, Figure 2H, and Table 2Table 2
Correlation of Positive and Negative Radioiodine Scan Findings after Administration of Thyrotropin and after Withdrawal of Thyroid Hormone in 127 Patients with Thyroid Carcinoma.). The scan obtained after administration of thyrotropin was superior (positive) in 3 patients (5 percent), and the scan obtained after withdrawal of thyroid hormone was superior in 18 patients (29 percent) (P = 0.001) (Table 3Table 3
Cancer Stage, Scan Class, and Serial Serum Thyroglobulin Concentrations in the 21 Patients with Discordant Radioiodine Scans after Thyrotropin Administration and after Withdrawal of Thyroid Hormone Therapy.). On the assumption that all activity outside the thyroid bed actually represented tumor, the staging of thyroid cancer would be similar in 40 of the 62 patients (65 percent), including 6 of the 11 patients with cervical activity outside the thyroid bed, 3 of the 4 patients with intrathoracic activity, and the 2 patients with radioiodine uptake in other distant regions.Among all 127 patients, including those who had concordant negative scans, the reviewers rated the scans obtained after administration of thyrotropin as equivalent (in 106 patients) or superior (in 3 patients) to those obtained after withdrawal of thyroid hormone in 86 percent and as inferior in 14 percent. The rates of concordant and discordant pairs of scans were similar whether or not the patient had received iodine-131 therapy previously.
There were no significant differences between patients with concordant scans and those with discordant scans in any of the following features: age, sex, weight, tumor type or extent of disease, previous radioiodine therapy, time since surgery or last iodine-131 treatment, activity of iodine-131 administered for scanning, serum thyrotropin concentrations or estimated urinary iodine excretion (data not shown) before administration of radioiodine for the two scans, time after withdrawal of thyroid hormone therapy, or investigational site.
Of the 18 patients for whom the scan obtained after withdrawal of thyroid hormone was superior, 10 were subsequently treated with iodine-131. Five received iodine-131 to ablate thyroid remnants and three to ablate cervical activity outside the thyroid bed that was seen only on the scan obtained after withdrawal of thyroid hormone. The serum thyroglobulin concentrations had increased after administration of thyrotropin in three of these patients. In the remaining two radioiodine-treated patients for whom the scans obtained after withdrawal of thyroid hormone were superior, both scans showed uptake in the thyroid bed, but the scans were categorized as discordant because one additional focus was identified on the scan obtained after withdrawal of thyroid hormone. Of the eight patients with a superior scan after withdrawal of thyroid hormone who were not treated with iodine-131, only thyroid-bed activity was seen in five patients, and a single focus outside the thyroid bed was seen in three patients, who were not treated because their serum thyroglobulin concentration was low (one patient) or an artifact was suspected (two patients).
Radioiodine Uptake after Thyrotropin Administration and after Thyroid Hormone Withdrawal
Among the 126 patients who had undergone thyroidectomy, the mean thyroid-bed uptake of iodine-131 was higher after withdrawal of thyroid hormone than after administration of thyrotropin according to thyroid-probe analysis (0.4±0.7 percent vs. 0.3±0.7 percent, P = 0.004) in 47 patients and region-of-interest analysis (0.5±0.9 percent vs. 0.3±0.6 percent, P = 0.02) in 30 patients. When the mean thyroidal uptake of radioiodine was corrected for the differences in whole-body retention of iodine-131, however, the average fractional-uptake value did not differ in scans obtained after administration of thyrotropin and scans obtained after withdrawal of thyroid hormone (data not shown).
Serum Thyroglobulin after Thyrotropin Administration and after Thyroid Hormone Withdrawal
Serum thyroglobulin was measured in 35 patients before administration of thyrotropin and at various intervals after their first dose of thyrotropin and after withdrawal of thyroid hormone. The serum thyroglobulin concentration increased to 5 μg per liter or more at some time in 15 patients. The increase occurred after thyrotropin administration in 13 patients and after withdrawal of thyroid hormone in 14 patients. The serum thyroglobulin concentration was higher after withdrawal of thyroid hormone in 11 patients and after administration of thyrotropin in 3 patients, and it was not precisely quantified by dilution studies in 1 patient. The serum thyroglobulin concentrations were highest 72 or 96 hours after the first dose of thyrotropin in the 33 patients studied at these times.
Clinical and Biochemical Changes after Thyrotropin Administration and after Thyroid Hormone Withdrawal
The patients had more symptoms after withdrawal of thyroid hormone than after administration of thyrotropin. There were statistically significant differences between the two study periods for all 14 symptoms and signs of hypothyroidism on the Billewicz Scale (weight gain, constipation, cold intolerance, slow movement, paresthesias, deafness, diminished sweating, hoarseness, dry skin, coarse skin, cold skin, puffiness, slowed ankle jerk, and decreased pulse rate) (P<0.001) and all 6 states of the Profile of Mood States (P<0.001).
The mean heart rate was slower after withdrawal of thyroid hormone than after administration of thyrotropin (78±12 vs. 68±11 beats per minute, P< 0.001). The patients had significantly higher mean serum concentrations of cholesterol (by 66 percent), triglycerides (by 70 percent), uric acid (by 24 percent), and creatinine (by 44 percent) after withdrawal of thyroid hormone than after administration of thyrotropin (P<0.001 for all).
Adverse Effects and Assessment of Antithyrotropin Antibodies
Of the 152 patients enrolled in the study, 48 (32 percent) had adverse events, which were interpreted by their treating physicians as definitely caused by thyrotropin in 6 patients, probably caused by it in 20, and possibly caused by it in 22. The only common adverse event was nausea, which occurred in 25 patients (16 percent), but was usually mild and short-lived. One patient with recurrent invasive thyroid carcinoma died of an apparent pulmonary embolus six days after administration of thyrotropin. No patient had detectable serum antithyrotropin antibodies, including seven who had received thyrotropin 7 to 16 months earlier.
Discussion
We found that recombinant thyrotropin was efficacious and safe for stimulating the uptake of radioiodine in patients with thyroid carcinoma who continued thyroid hormone therapy, but not as effective as withdrawal of thyroid hormone. Treatment with thyrotropin averted the hypothyroid symptoms and mood disorders that occur after withdrawal of thyroid hormone. In 71 percent of patients with a positive scan obtained by one or both techniques, the scan obtained after the administration of thyrotropin was equivalent or superior to the one obtained after withdrawal of thyroid hormone, whereas the latter was superior in the remaining 29 percent. Conversely, the scans obtained after withdrawal of thyroid hormone were equivalent or superior to those obtained after administration of thyrotropin in 95 percent of the patients with a positive scan. When patients with negative scans — the finding most commonly encountered in patients who have previously received radioiodine therapy — were included, the scans obtained after administration of thyrotropin were equivalent or superior to those obtained after withdrawal of thyroid hormone in 86 percent of the patients.
Although the scans obtained after withdrawal of thyroid hormone were rated superior by the independent reviewers in more than one quarter of the patients, the clinical importance of the difference is uncertain. Of 12 patients with uptake in the thyroid bed on the post-withdrawal scan alone, 5 were treated with radioiodine, a difference that reflects the variability in practice with regard to radioiodine therapy in this circumstance. Of the six patients with additional iodine-avid lesions outside the thyroid bed demonstrated only by the post-withdrawal scan, three were treated with radioiodine. Both scans were positive in the seven patients with other metastases subsequently treated with radioiodine. The additional information provided by the withdrawal of thyroid hormone must be balanced against the symptoms that occur in most patients when they are hypothyroid for several weeks.
There are two possible explanations for the discordant scans. First, radioiodine clearance is decreased in hypothyroidism, resulting in higher bioavailability of radioiodine for imaging after withdrawal of thyroid hormone.23 Second, the degree and duration of stimulation by thyrotropin produced by the dosing regimen in this study may not be optimal. Protocols producing more prolonged stimulation by thyrotropin, mimicking more closely that which follows withdrawal of thyroid hormone, might be superior.
A limitation of the study design was that the sequence of the two scans was not randomized. It would have been inappropriate if a patient for whom radioiodine therapy was indicated by a positive scan on withdrawal of thyroid hormone or by an elevated serum thyroglobulin concentration had been required to resume thyroid hormone therapy so that another scan could be obtained after administration of thyrotropin, because this second scanning would delay radioiodine therapy. It is possible that the radioiodine administered for the first scan might have “stunned” residual iodine-avid thyroid tissue, decreasing the sensitivity of the scanning after withdrawal of thyroid hormone. However, this seems unlikely, because 96 percent of the post-withdrawal scans proved to be positive in patients with preceding positive thyrotropin scans, the fractional radioiodine uptake in thyroid tissue was actually higher after radioiodine dosing for the second scan, and “stunning” occurs more often with higher doses of radioiodine for scanning than were used in this study.24
Measurement of serum thyroglobulin is a valuable technique for detecting residual or recurrent thyroid carcinoma.6,7 Although assessment of thyrotropin-mediated thyroglobulin stimulation was not a primary end point of this study, the results in a subgroup of patients demonstrate that exogenous thyrotropin is capable of stimulating the release of thyroglobulin. This finding suggests that administration of thyrotropin may increase the sensitivity of serum thyroglobulin as a tumor marker.
The fact that with radioiodine scanning after the administration of thyrotropin one can avert the hypothyroidism that occurs after the withdrawal of thyroid hormone therapy is potentially clinically important. The consequences of even short-term hypothyroidism — in terms of impaired work performance, personal safety, and interpersonal relations — are familiar to physicians who have cared for patients requiring periodic discontinuation of thyroid hormone therapy for radioiodine scanning. Although a recent small study25 suggested that partial withdrawal of thyroid hormone can facilitate scanning while minimizing symptoms, this approach will require more evaluation. Furthermore, after withdrawal of thyroid hormone, the prolonged rise in serum thyrotropin, which has tropic effects on residual thyroid-cancer tissue, can promote tumor progression, with potentially serious clinical consequences, particularly in patients with central nervous system metastases.9-11
Thyrotropin was well tolerated by most patients in this study. The side effects were limited to nausea, which was short-lived and mild in most patients. An antithyrotropin immunoglobulin response was not detected, even among patients who had previously received thyrotropin.
In conclusion, thyrotropin was effective in stimulating the uptake of radioiodine for scanning in patients who had been treated for thyroid cancer. Thyrotropin-mediated diagnostic scans were as sensitive as those obtained after withdrawal of thyroid hormone in the majority of patients, but 29 percent of the patients with positive scans had superior scans after withdrawal of thyroid hormone. This resulted in more advanced tumor staging in 6 percent of the patients and led to radioiodine treatment of 13 percent of the patients. Thyrotropin also stimulates the production of thyroglobulin by residual thyroid tissue, which may increase the usefulness of this tumor marker in patients treated with thyroid hormone who have had thyroid tissue ablated. The patients had significantly fewer symptoms when they were taking thyrotropin and continuing thyroid hormone therapy than when they discontinued thyroid hormone therapy.
We are indebted to Juan Francisco Fierro, M.D., Colum A. Gorman, M.D., Gregory A. Ledger, M.D., S.-G. Park, M.D., Gregory Randolph, M.D., Christine Schneyer, M.D., Monica Skarulis, M.D., Irini Veronikis, M.D., Steven Tollin, M.D., Maralyn Valentine, M.D., Karen M. Auwaerter, R.N., Craig Cochran, R.N., Sheryl M. Ness, R.N., Roxanne Schock, R.N., Naomi Walpert, R.N., M.S., Millie Whatley, N.M.T., and Bernadette White, R.N., who skillfully contributed to these studies and to the care of the patients; and to Ms. Deirdre Maxted for assistance with study coordination and data analyses.
Source Information
From the Division of Endocrinology and Metabolism and the Thyroid Tumor Center, Johns Hopkins University School of Medicine, Baltimore (P.W.L.); the Division of Endocrinology and Metabolism, University of Massachusetts Medical Center, Worcester (L.E.B.); the Department of Internal Medicine, Ohio State University, Columbus (E.L.M.); the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md. (F.B.-D., B.D.W.); the Division of Endocrinology and Metabolism, Sinai Hospital of Baltimore, Baltimore (D.S.C.); the Division of Endocrinology and Metabolism (J.R.G.) and the Thyroid Unit (F.E.W.), Beth Israel Hospital, Boston; the Division of Endocrinology and Metabolism, Mount Sinai Medical Center, New York (T.F.D.); the Thyroid Study Unit, University of Chicago Medical Center, Chicago (L.J.D.); and the Thyroid Unit, Massachusetts General Hospital, Boston (G.H.D., D.S.R.).
Address reprint requests to Dr. Ladenson at the Division of Endocrinology and Metabolism, Johns Hopkins Hospital, 600 N. Wolfe St., Baltimore, MD 21287-4904.
Other authors were Ian D. Hay, M.D., Ph.D. (Division of Endocrinology, Mayo Clinic and Foundation, Rochester, Minn.), Silvina Levis, M.D. (Division of Endocrinology, University of Miami School of Medicine, Miami), James C. Reynolds, M.D. (National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.), Jacob Robbins, M.D. (National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.), David V. Becker, M.D. (New York Hospital, Cornell Medical Center, New York), Ralph R. Cavalieri, M.D. (Veterans Affairs Medical Center, San Francisco), Harry R. Maxon, M.D. (University of Cincinnati Medical Center, Cincinnati), Kevin McEllin (Genzyme Corporation, Cambridge, Mass.), and Richard Moscicki, M.D. (Genzyme Corporation, Cambridge, Mass.).
- References
References
1
Cancer facts and figures. Atlanta: American Cancer Society, 1995.
2
Robbins J ,Merino MJ ,Boice JD Jr , et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991;115:133-147
Web of Science | Medline3
Mazzaferri EL ,Jhiang SM . Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428[Erratum, J Med 1995;98:215.]
CrossRef | Web of Science | Medline4
Maxon HR III ,Smith HS . Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990;19:685-718
Web of Science | Medline5
Goldman JM ,Line BR ,Aamodt RL ,Robbins J . Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980;50:734-739
CrossRef | Web of Science | Medline6
Ozata M ,Suzuki S ,Miyamoto T ,Liu RT ,Fierro-Renoy F ,DeGroot LJ . Serum thyroglobulin in the follow-up of patients treated with differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105
CrossRef | Web of Science | Medline7
Pacini F ,Pinchera A ,Giani C ,Grasso L ,Baschieri L . Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol (Oxf) 1980;13:107-110
CrossRef | Web of Science | Medline8
Ringel MD ,Ladenson PW . Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996;81:1724-1725
CrossRef | Web of Science | Medline9
Maloof F ,Vickery AL ,Rapp B . An evaluation of various factors influencing the treatment of metastatic thyroid carcinoma with I131. J Clin Endocrinol Metab 1956;16:1-27
CrossRef | Web of Science | Medline10
Sfakianakis GN ,Skillman TG ,George JM . Thyroxine withdrawal in thyroid cancer. Ohio State Med J 1975;71:79-82
Medline11
Goldberg LD ,Ditchek NT . Thyroid carcinoma with spinal cord compression. JAMA 1981;245:953-954
CrossRef | Web of Science | Medline12
Sturgeon CT ,Davis FE ,Catz B ,Petit D ,Starr P . Treatment of thyroid cancer metastases with TSH and I131 during thyroid hormone medication. J Clin Endocrinol Metab 1953;13:1391-1407
CrossRef | Web of Science | Medline13
Benua RS ,Sonenberg M ,Leeper RD ,Rawson RW . An 18 year study of the use of beef thyrotropin to increase I131 uptake in metastatic thyroid cancer. J Nucl Med 1964;5:796-801
Web of Science14
Szkudlinski MW ,Thotakura NR ,Bucci I , et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 1993;133:1490-1503
CrossRef | Web of Science | Medline15
Thotakura NR ,Desai RK ,Bates LG ,Cole ES ,Pratt BM ,Weintraub BD . Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 1991;128:341-348
CrossRef | Web of Science | Medline16
Huber GK ,Fong P ,Concepcion ES ,Davies TF . Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1991;72:1328-1331
CrossRef | Web of Science | Medline17
Braverman LE ,Pratt BM ,Ebner S ,Longcope C . Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the Rhesus monkey. J Clin Endocrinol Metab 1992;74:1135-1139
CrossRef | Web of Science | Medline18
Meier CA ,Braverman LE ,Ebner SA , et al. Diagnostic use of human recombinant thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994;78:188-196
CrossRef | Web of Science | Medline19
Cole ES ,Lee K ,Lauziere K , et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology 1993;11:1014-1024
CrossRef | Web of Science | Medline20
Benotti J ,Benotti N ,Pino S ,Gardyna H . Determination of total iodine in urine, stool, diets, and tissue. Clin Chem 1965;11:932-936
Web of Science | Medline21
Billewicz WZ ,Chapman RS ,Crooks J , et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969;38:255-266
Web of Science | Medline22
Shacham S . A shortened version of the Profile of Mood States. J Pers Assess 1983;47:305-306
CrossRef | Web of Science | Medline23
Park S-G ,Reynolds JC ,Brucker-Davis F , et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs. hypothyroidism. J Nucl Med 1996;37:Suppl:15P-15P abstract.24
Park H-M ,Perkins OW ,Edmondson JW ,Schnute RB ,Manatunga A . Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54
CrossRef | Web of Science | Medline25
Guimaraes V ,DeGroot LJ . Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. Thyroid 1996;6:69-73
CrossRef | Web of Science | Medline
- Citing Articles (126)
Citing Articles
1
Ivana Zagar, Andreja A. Schwarzbartl-Pevec, Barbara Vidergar-Kralj, Rika Horvat, Nikola Besic. (2012) Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma. Journal of Thyroid Research 2012, 1-11
CrossRef2
Ik Dong Yoo, Sung Hoon Kim, Ye Young Seo, Jin Kyoung Oh, Joo Hyun O, Soo Kyo Chung. (2011) The Success Rate of Initial 131I Ablation in Differentiated Thyroid Cancer: Comparison Between Less Strict and Very Strict Low Iodine Diets. Nuclear Medicine and Molecular Imaging
CrossRef3
Herbert A. Klein. (2011) Radioiodine Dilution Due to Levothyroxine When Using Recombinant Human Thyroid-Stimulating Hormone. Clinical Nuclear Medicine 36:10, 899-903
CrossRef4
Margareta Dobrenic, Drazen Huic, Marijan Zuvic, Darko Grosev, Ratimir Petrovic, Tatjana Samardzic. (2011) Usefulness of low iodine diet in managing patients with differentiated thyroid cancer - initial results. Radiology and Oncology 45:3, 189-195
CrossRef5
Silvana Balzan, Angelo Carpi, Monica Evangelista, Giuseppina Nicolini, Alberto Pollastri, Antonio Bottoni, Giorgio Iervasi. (2011) Acute effect of TSH on oxygenation state and volume of erythrocytes from subjects thyroidectomized for differentiated thyroid carcinoma. Biomedicine & Pharmacotherapy 65:5, 381-384
CrossRef6
Julia Reinfelder, Simone Maschauer, Catherine A. Foss, Sridhar Nimmagadda, Valerie Fremont, Vladimir Wolf, Bruce D. Weintraub, Martin G. Pomper, Mariusz W. Szkudlinski, Torsten Kuwert, Olaf Prante. (2011) Effects of Recombinant Human Thyroid-Stimulating Hormone Superagonists on Thyroidal Uptake of 18 F-Fluorodeoxyglucose and Radioiodide. Thyroid 21:7, 783-792
CrossRef7
Josef Machac. 2011. The Use of Diagnostic Radiotracers in Thyroid Cancer. , 133-181.
CrossRef8
Hendrieke C Hoftijzer, Ellen Kapiteijn, Tatiana Schneider, Guido C Hovens, Hans Morreau, Hans Gelderblom, Johannes WA Smit. (2011) Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. Clinical Investigation 1:2, 241-253
CrossRef9
Lutz Stefan Freudenberg, Walter Jentzen, Thorsten Petrich, Cornelia Frömke, Robert J. Marlowe, Till Heusner, Wolfgang Brandau, Wolfram H. Knapp, Andreas Bockisch. (2010) Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. European Journal of Nuclear Medicine and Molecular Imaging 37:12, 2267-2276
CrossRef10
Rebecca Over, Hala Nsouli-Maktabi, Kenneth D. Burman, Jacqueline Jonklaas. (2010) Age Modifies the Response to Recombinant Human Thyrotropin. Thyroid 20:12, 1377-1384
CrossRef11
Chao Ma, Jiawei Xie, Wanxia Liu, Guoming Wang, Shuyao Zuo, Xufu Wang, Fengyu Wu, Chao Ma. 2010. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. .
CrossRef12
Ming-Kai Chen, Indukala Doddamane, David W Cheng. (2010) Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. Current Opinion in Oncology 22:1, 6-10
CrossRef13
(2009) Sudden onset of haemoptysis and hypoxia after recombinant human thyroid-stimulating hormone use in a patient with papillary thyroid carcinoma and pulmonary metastases. Internal Medicine Journal 39:12, 854-855
CrossRef14
Paolo Zanotti-Fregonara, Elif Hindié, Marie Elisabeth Toubert, Domenico Rubello. (2009) What role for recombinant human TSH in the treatment of metastatic thyroid cancer?. European Journal of Nuclear Medicine and Molecular Imaging 36:6, 883-885
CrossRef15
Beatriz Rodríguez-Merchán, Jordi Mesa. (2009) Una década de tirotropina recombinante humana. Medicina Clínica 132:14, 560-564
CrossRef16
R. Wong, D. J. Topliss, L. A. Bach, P. S. Hamblin, V. Kalff, F. Long, J. R. Stockigt. (2009) Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution. Internal Medicine Journal 39:3, 156-163
CrossRef17
Michael A Rosenbaum, Christopher R McHenry. (2009) Contemporary management of papillary carcinoma of the thyroid gland. Expert Review of Anticancer Therapy 9:3, 317-329
CrossRef18
Hiroshi Kishida. (2009) Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen® Intramuscular Injection 0.9 mg). Folia Pharmacologica Japonica 134:1, 28-34
CrossRef19
Furio Pacini, Maria Grazia Castagna. (2008) Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Practice & Research Clinical Endocrinology & Metabolism 22:6, 1009-1021
CrossRef20
M. Luster, S. E. Clarke, M. Dietlein, M. Lassmann, P. Lind, W. J. G. Oyen, J. Tennvall, E. Bombardieri. (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 35:10, 1941-1959
CrossRef21
Celestino Pio Lombardi, Maurizio Bossola, Pietro Princi, Mauro Boscherini, Giuseppe La Torre, Marco Raffaelli, Emanuela Traini, Massimo Salvatori, Alfredo Pontecorvi, Rocco Bellantone. (2008) Circulating thyroglobulin mRNA does not predict early and midterm recurrences in patients undergoing thyroidectomy for cancer. The American Journal of Surgery 196:3, 326-332
CrossRef22
Bryan R. Haugen, David S. Cooper, Charles H. Emerson, Markus Luster, Rui M.B. Maciel, Rosa P.M. Biscolla, Ernest L. Mazzaferri, Geraldo Medeiros-Neto, Christoph Reiners, Richard J. Robbins, Bruce G. Robinson, Martin Schlumberger, Shunichi Yamashita, Furio Pacini. (2008) Expanding Indications for Recombinant Human TSH in Thyroid Cancer. Thyroid 18:7, 687-694
CrossRef23
Paolo Zanotti-Fregonara, Domenico Rubello, Elif Hindié. (2008) Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. European Journal of Nuclear Medicine and Molecular Imaging 35:7, 1397-1399
CrossRef24
G. Martínez Díaz-Guerra, A. Serraclara Pla, E. Jódar Gimeno, F. Hawkins Carranza. (2008) Patología tiroidea. Clasificación. Evaluación de la función tiroidea. Anticuepos antitiroideos. Tiroglobulina. Imagen en tiroides: ultrasonografía, gammagrafía, TAC y PET. Punción-aspiración de tiroides. Medicine - Programa de Formación Médica Continuada Acreditado 10:14, 889-897
CrossRef25
Leonidas H. Duntas, David S. Cooper. (2008) Review on the Occasion of a Decade of Recombinant Human TSH: Prospects and Novel Uses. Thyroid 18:5, 509-516
CrossRef26
G.-C. Rutherford, B. Franc, A. O'Connor. (2008) Nuclear medicine in the assessment of differentiated thyroid cancer. Clinical Radiology 63:4, 453-463
CrossRef27
Benjamin Leader, Quentin J. Baca, David E. Golan. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery 7:1, 21-39
CrossRef28
Paolo Zanotti-Fregonara, Elif Hindié, Isabelle Keller, Marie Calzada-Nocaudie, Jean-Yves Devaux. (2007) Scintigraphic Visualization of Glossal Thyroid Tissue During the Follow-up of Thyroid Cancer Patients. Clinical Nuclear Medicine 32:12, 911-914
CrossRef29
Marguerite T. Parisi, David Mankoff. (2007) Differentiated Pediatric Thyroid Cancer: Correlates With Adult Disease, Controversies in Treatment. Seminars in Nuclear Medicine 37:5, 340-356
CrossRef30
Silvana Balzan, Giuseppina Nicolini, Francesca Forini, Giuseppe Boni, Renata Del Carratore, Andrea Nicolini, Angelo Carpi, Giorgio Iervasi. (2007) Presence of a functional TSH receptor on human erythrocytes. Biomedicine & Pharmacotherapy 61:8, 463-467
CrossRef31
D. Barbaro, G. Boni. (2007) Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: Why, how and when. European Journal of Surgical Oncology (EJSO) 33:5, 535-540
CrossRef32
Y. Nancy You, Samuel A. Wells. (2007) Role of Surgeons in Clinical Trials for Thyroid Cancer. World Journal of Surgery 31:5, 987-995
CrossRef33
Paolo Zanotti-Fregonara, Fran??oise Duron, Isabelle Keller, Alexandre Khoury, Jean-Yves Devaux, Elif Hindi??. (2007) Stimulation test in the follow-up of thyroid cancer: Plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values. Nuclear Medicine Communications 28:4, 257-259
CrossRef34
Paolo Zanotti-Fregonara, Alexandre Khoury, Françoise Duron, Isabelle Keller, Sophie Christin-Maître, Thierry Kiffel, Marie Elisabeth Toubert, Jean-Yves Devaux, Elif Hindié. (2007) Which thyroid cancer patients need periodic stimulation tests?. European Journal of Nuclear Medicine and Molecular Imaging 34:4, 541-546
CrossRef35
Philip Goldberg. (2007) Life-Threatening Hypothyroidism During Thyroid Hormone Withdrawal for Routine Thyroid Cancer Surveillance. The Endocrinologist 17:2, 116-118
CrossRef36
Angela Vaiano, A. Claudio Traino, Giuseppe Boni, Mariano Grosso, Patrizia Lazzeri, Chiara Colato, Maria Vittoria Dav??, Giorgio Francia, Mauro Lazzeri, Giuliano Mariani, Marco Ferdeghini. (2007) Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. Nuclear Medicine Communications 28:3, 215-223
CrossRef37
Ryan D. Niederkohr, I Ross McDougall. (2007) Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin. European Journal of Nuclear Medicine and Molecular Imaging 34:3, 363-367
CrossRef38
Sophie Leboulleux, Pamela R Schroeder, Martin Schlumberger, Paul W Ladenson. (2007) The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice Endocrinology & Metabolism 3:2, 112-121
CrossRef39
E.L. Mazzaferri. (2007) Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. Yearbook of Endocrinology 2007, 267-269
CrossRef40
Atsushi KUMAGAI, Christoph REINERS, Valentina DROZD, Shunichi YAMASHITA. (2007) Childhood Thyroid Cancers and Radioactive Iodine Therapy: Necessity of Precautious Radiation Health Risk Management. Endocrine Journal 54:6, 839-847
CrossRef41
Martin Schlumberger, Isabelle Borget, Gérard De Pouvourville, Furio Pacini. (2007) Recombinant Human Thyroid-Stimulating Hormone: Use in Papillary and Follicular Thyroid Cancer. Hormone Research 67:1, 132-142
CrossRef42
Alessandro Antonelli, Paolo Miccoli, Poupak Fallahi, Silvia Martina Ferrari, Mariano Grosso, Giuseppe Boni, Piero Berti. (2006) Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. Surgery 140:6, 1035-1042
CrossRef43
A. Iervasi, G. Iervasi, A. Carpi, G.C. Zucchelli. (2006) Serum thyroglobulin measurement: clinical background and main methodological aspects with clinical impact. Biomedicine & Pharmacotherapy 60:8, 414-424
CrossRef44
A.P. Caresia, J. Castell Conesa, G. Obiols Alfonso, P. Pifarré Montaner, M. Negre Busó, C. García Alonso, P. Galofré Mora, J. Mesa manteca. (2006) Estudio comparativo entre la utilización de TSH recombinante y la estimulación endógena con TSH. Valoración en el seguimiento de los pacientes con carcinoma diferenciado de tiroides. Revista Española de Medicina Nuclear 25:4, 236-241
CrossRef45
Felix Sundram, Bruce G. Robinson, Annie Kung, Mary Anne Lim-Abrahan, Nguyen Quang Bay, Loh Keh Chuan, Jae Hoon Chung, Shih-Ming Huang, Li-Cho Hsu, Norazmi Kamaruddin, Wei Keat Cheah, Won Bae Kim, Sung-Soo Koong, Hong Da Lin, Ampica Mangklabruks, Elizabeth Paz-Pacheco, Abu Rauff, Paul W. Ladenson. (2006) Well-Differentiated Epithelial Thyroid Cancer Management in the Asia Pacific Region: A Report and Clinical Practice Guideline. Thyroid 16:5, 461-469
CrossRef46
Sefik Tagay, Stephan Herpertz, Matthias Langkafel, Yesim Erim, Andreas Bockisch, Wolfgang Senf, Rainer Görges. (2006) Health-related Quality of Life, Depression and Anxiety in Thyroid Cancer Patients. Quality of Life Research 15:4, 695-703
CrossRef47
George Saab, Albert A. Driedger, William Pavlosky, Tom McDonald, Ching-Yee O. Wong, John Yoo, Jean-Luc Urbain. (2006) Thyroid-Stimulating Hormone–Stimulated Fused Positron Emission Tomography/Computed Tomography in the Evaluation of Recurrence in 131 I-Negative Papillary Thyroid Carcinoma. Thyroid 16:3, 267-272
CrossRef48
Marius E Kraenzlin, Christian Meier. (2006) Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer. Expert Opinion on Biological Therapy 6:2, 167-176
CrossRef49
Min Ah Na, Sun Hae Shin, Yang Ho Kang, Seok Man Son, In Joo Kim, Yong Ki Kim. (2006) A Retrospective Review of the Effectiveness of Recombinant Human TSH-Aided Radioiodine Treatment of Differentiated Thyroid Carcinoma. Journal of Korean Endocrine Society 21:4, 274
CrossRef50
Kiminori SUGINO, Koichi ITO, Hiroshi TAKAMI. (2006) Management of Differentiated Thyroid Carcinoma with Radioiodine and Recombinant Human TSH. Endocrine Journal 53:6, 723-728
CrossRef51
Tae Sik Jung, Hye Seung Jung, Jung Hwa Jung, Yun Jae Chung, Eun Young Oh, Young-Ki Min, Myung-Shik Lee, Moon-Kyu Lee, Kwang-Won Kim, Jae Hoon Chung. (2006) Analysis of the Pharmacokinetics of Recombinant Human TSH in Patients with Thyroid Papillary Carcinoma. Journal of Korean Endocrine Society 21:3, 204
CrossRef52
Pedro Weslley Souza Ros??rio, Tales Alvarenga Fagundes, Leonardo Lamego Rezende, Eduardo Lanza Padrao, Michelle Aparecida Ribeiro Borges, Alvaro Lu??s Barroso. (2006) Assessing Hypothyroidism in the Preparation of Patients With Thyroid Cancer. The Endocrinologist 16:1, 25-29
CrossRef53
Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph Reiners. (2005) Thyroid Hormone Withdrawal in Patients with Differentiated Thyroid Carcinoma: A One Hundred Thirty-Patient Pilot Survey on Consequences of Hypothyroidism and a Pharmacoeconomic Comparison to Recombinant Thyrotropin Administration. Thyroid 15:10, 1147-1155
CrossRef54
Orlo H. Clark. (2005) Invited Commentary. World Journal of Surgery 29:8, 1011-1012
CrossRef55
M.D. Abós Olivares, C. Pesquera González. (2005) Controversias en el seguimiento del carcinoma diferenciado de tiroides. Nuevas respuestas a viejas cuestiones. Revista Española de Medicina Nuclear 24:3, 207-215
CrossRef56
J.M. Jiménez-Hoyuela García, J.M. García Almeida, A. Delgado García, I. Aguilar Fernández, M.D. Martínez del Valle Torres, S. Ortega Lozano, A. Rebollo Aguirre, I. Mancha Doblas, J.L. Pinzón Martín, M.J. Picón César, D. Zamorano Vázquez. (2005) Aplicación de la TSH humana recombinante en el protocolo diagnóstico del cáncer diferenciado de tiroides. Revista Española de Medicina Nuclear 24:3, 152-160
CrossRef57
R.J. Prestwich, G.E. Gerrard. (2005) Low-iodine diet before radioiodine uptake scans or therapy — flawed advice to UK patients. Clinical Oncology 17:2, 73-74
CrossRef58
Alessia David, Annabella Blotta, Roberta Rossi, Maria Chiara Zatelli, Marta Bondanelli, Elio Roti, Lewis E. Braverman, Luciano Busutti, Ettore C. degli Uberti. (2005) Clinical Value of Different Responses of Serum Thyroglobulin to Recombinant Human Thyrotropin in the Follow-Up of Patients with Differentiated Thyroid Carcinoma. Thyroid 15:3, 267-273
CrossRef59
Derek T. Woodrum, Paul G. Gauger. (2005) Role of131I in the treatment of well differentiated thyroid cancer. Journal of Surgical Oncology 89:3, 114-121
CrossRef60
Terry F. Davies. (2005) An Interview with Lewis E. Braverman M.D.. Thyroid 15:3, 188-196
CrossRef61
Alessia David, Annabella Blotta, Roberta Rossi, Maria Chiara Zatelli, Marta Bondanelli, Elio Roti, Lewis E. Braverman, Luciano Busutti, Ettore C. degli Uberti. (2005) Clinical Value of Different Responses of Serum Thyroglobulin to Recombinant Human Thyrotropin in the Follow-Up of Patients with Differentiated Thyroid Carcinoma. Thyroid 15:2, 158-164
CrossRef62
Stephen Blamey, Bruce Barraclough, Leigh Delbridge, Paul Mernagh, Lachlan Standfield, Adele Weston. (2005) Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer. ANZ Journal of Surgery 75:1-2, 10-20
CrossRef63
Viveque Egsgaard Nielsen, Steen Joop Bonnema, Laszlo Hegedus. (2004) The effects of recombinant human thyrotropin, in normal subjects and patients with goitre. Clinical Endocrinology 61:6, 655-663
CrossRef64
Loukas Gourgiotis, Monica C Skarulis. (2004) Clinical uses of recombinant human thyrotropin. Expert Opinion on Pharmacotherapy 5:12, 2503-2514
CrossRef65
Mariusz W Szkudlinski. (2004) Recombinant human thyrotropins of the twenty-first century. Expert Opinion on Pharmacotherapy 5:12, 2435-2440
CrossRef66
Judy E. Kalinyak, I. Ross McDougall. (2004) Whole-body scanning with radionuclides of iodine, and the controversy of ???thyroid stunning???. Nuclear Medicine Communications 25:9, 883-889
CrossRef67
Ujjal K. Mallick, Haris Charalambous. (2004) Current issues in the management of differentiated thyroid cancer. Nuclear Medicine Communications 25:9, 873-881
CrossRef68
Whitney W. Woodmansee, Bryan R. Haugen. (2004) A review of the potential uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clinical Endocrinology 61:2, 163-173
CrossRef69
C. F. A. Eustatia-Rutten, J. W. A. Smit, J. A. Romijn, E. P. M. van der Kleij-Corssmit, A. M. Pereira, M. P. Stokkel, J. Kievit. (2004) Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clinical Endocrinology 61:1, 61-74
CrossRef70
D. Taïeb, T. Jacob, E. Zotian, O. Mundler. (2004) Lack of Efficacy of Recombinant Human Thyrotropin Versus Thyroid Hormone Withdrawal for Radioiodine Therapy Imaging in a Patient with Differentiated Thyroid Carcinoma Lung Metastases. Thyroid 14:6, 465-467
CrossRef71
D. Taïeb, D. Lussato, O. Mundler. (2004) Subcutaneous Administration of Recombinant Human Thyrotropin as an Alternative to Thyroid Hormone Withdrawal in Patients with Anticoagulated Thyroid Cancer: Preliminary Results. Thyroid 14:6, 463-464
CrossRef72
Edelmiro Menéndez Torre, María Teresa López Carballo, Rosa María Rodríguez Erdozáin, Lluís Forga Llenas, María José Goñi Iriarte, Juan José Barbería Layana. (2004) Prognostic Value of Thyroglobulin Serum Levels and 131 I Whole-Body Scan after Initial Treatment of Low-Risk Differentiated Thyroid Cancer. Thyroid 14:4, 301-306
CrossRef73
Caroline GP Roberts, Paul W Ladenson. (2004) Hypothyroidism. The Lancet 363:9411, 793-803
CrossRef74
Dyde A. Huysmans, Willy-Anne Nieuwlaat, Ad R. Hermus. (2004) Towards larger volume reduction of nodular goitres by radioiodine therapy: a role for pretreatment with recombinant human thyrotropin?. Clinical Endocrinology 60:3, 297-299
CrossRef75
Joel T. Park, James V. Hennessey. (2004) Two-Week Low Iodine Diet Is Necessary for Adequate Outpatient Preparation for Radioiodine rhTSH Scanning in Patients Taking Levothyroxine. Thyroid 14:1, 57-63
CrossRef76
Rebecca A. Sendak, Chandrashekar Ganesa, Karen L. Lee, John J. Harrahy, Roger Théberge, Charles J. Morgan, Edward S. Cole, Leonard D. Kohn, Robert J. Mattaliano. (2003) The Effect of Posttranslational Modifications on the In Vitro Activity of Recombinant Human Thyroid-Stimulating Hormone. Thyroid 13:12, 1091-1101
CrossRef77
Jason B. Cohen, Judy E. Kalinyak, I. Ross McDougall. (2003) Modern Management of Differentiated Thyroid Cancer. Cancer Biotherapy & Radiopharmaceuticals 18:5, 689-705
CrossRef78
Laura Fugazzola, Luca Persani, Deborah Mannavola, Eugenio Reschini, Guia Vannucchi, Giovanna Weber, Paolo Beck-Peccoz. (2003) Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during l-thyroxine replacement. Clinical Endocrinology 59:2, 230-236
CrossRef79
Joaquin Lado-Abeal, Eleonora Molinaro, Erin DeValk, Furio Pacini, Samuel Refetoff. (2003) The Effect of Short-Term Treatment with Recombinant Human Thyroid-Stimulating Hormones on Leydig Cell Function in Men. Thyroid 13:7, 649-652
CrossRef80
MR CARLISLE, C LU, I ROSS McDOUGALL. (2003) The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nuclear Medicine Communications 24:6, 715-735
CrossRef81
Gabriella Pellegriti, Claudia Scollo, Concetto Regalbuto, Marco Attard, Paola Marozzi, Francesco Vermiglio, Maria Antonella Violi, Michelangela Cianci, Riccardo Vigneri, Vincenzo Pezzino, Sebastiano Squatrito. (2003) The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clinical Endocrinology 58:5, 556-561
CrossRef82
Maurice J. H. M. Pluijmen, Carmen Eustatia-Rutten, Bernard M. Goslings, Marcel P. Stokkel, Alberto M. Pereira Arias, Michaela Diamant, Johannes A. Romijn, Jan W. A. Smit. (2003) Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clinical Endocrinology 58:4, 428-435
CrossRef83
João Ezequiel de Oliveira, Fernanda de Mendonça, Cibele N Peroni, Paolo Bartolini, Maria Teresa C.P Ribela. (2003) Determination of Chinese hamster ovary cell-derived recombinant thyrotropin by reversed-phase liquid chromatography. Journal of Chromatography B 787:2, 345-355
CrossRef84
GREGORY S. ANDERSON, STEPHANIE FISH, KHOZAIM NAKHODA, HONGMING ZHUANG, ABASS ALAVI, SUSAN J. MANDEL. (2003) Comparison of I-123 and I-131 for Whole-Body Imaging After Stimulation by Recombinant Human Thyrotropin. Clinical Nuclear Medicine 28:2, 93-96
CrossRef85
ALDO N. SERAFINI, RALF P. CLAUSS, SILVINA LEVIS-DUSSEAU. (2003) Protocol for the Combined Diagnostic and Therapeutic Use of Recombinant Human Thyroid-Stimulating Hormone. Clinical Nuclear Medicine 28:1, 14-17
CrossRef86
Charles H. Emerson, Mira S.T. Torres. (2003) Recombinant Human Thyroid-Stimulating Hormone. BioDrugs 17:1, 19-38
CrossRef87
STEPHANIE A. FISH, ABASS ALAVI, SUSAN J. MANDEL. (2002) I-123 Imaging After Recombinant Human Thyroid-Stimulating Hormone to Diagnose Metastatic Disease in an Intubated Patient with Papillary Thyroid Cancer. Clinical Nuclear Medicine 27:12, 895
CrossRef88
Gregory W. Randolph, Gilbert H. Daniels. (2002) Radioactive Iodine Lobe Ablation as an Alternative to Completion Thyroidectomy for Follicular Carcinoma of the Thyroid. Thyroid 12:11, 989-996
CrossRef89
Paul W. Ladenson. (2002) Psychological wellbeing in patients. Clinical Endocrinology 57:5, 575-576
CrossRef90
Wellington Hung, Nicholas J. Sarlis. (2002) Current Controversies in the Management of Pediatric Patients with Well-Differentiated Nonmedullary Thyroid Cancer: A Review. Thyroid 12:8, 683-702
CrossRef91
WILLIAM R. ROBESON, JOANMARIE E. ELLWOOD, PAUL MARGULIES, DONALD MARGOULEFF. (2002) Outcome and Toxicity Associated with Maximum Safe Dose Radioiodine Treatment of Metastatic Thyroid Cancer. Clinical Nuclear Medicine 27:8, 556-566
CrossRef92
Leonard Wartofsky. (2002) Management of Low-Risk Well-Differentiated Thyroid Cancer Based Only on Thyroglobulin Measurement After Recombinant Human Thyrotropin. Thyroid 12:7, 583-590
CrossRef93
S. Haber. (2002) Guest Editorial: Recombinant Human TSH Testing for Recurrent Thyroid Cancer: A Re-appraisal. Thyroid 12:7, 599-602
CrossRef94
Anthony Toft, Geoffrey Beckett. (2002) Use of recombinant thyrotropin. The Lancet 359:9321, 1874-1875
CrossRef95
Vitale Giovanni, Lupoli Gelsy Arianna, Ciccarelli Antonio, Fonderico Francesco, Klain Michele, Squame Giovanni, Salvatore Marco, Lupoli Giovanni. (2002) The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clinical Endocrinology 56:2, 247-252
CrossRef96
Bryan R. Haugen, E. Chester Ridgway, Beverly A. McLaughlin, Michael T. McDermott. (2002) Clinical Comparison of Whole-Body Radioiodine Scan and Serum Thyroglobulin After Stimulation with Recombinant Human Thyrotropin. Thyroid 12:1, 37-43
CrossRef97
G. Pellegriti, C. Scollo, D. Giuffrida, R. Vigneri, S. Squatrito, V. Pezzino. (2001) Usefulness of Recombinant Human Thyrotropin in the Radiometabolic Treatment of Selected Patients with Thyroid Cancer. Thyroid 11:11, 1025-1030
CrossRef98
Rocco Bellantone, Celestino Pio Lombardi, Maurizio Bossola, Angela Ferrante, Pietro Princi, Mauro Boscherini, Ludovica Maussier, Massimo Salvatori, Vittoria Rufini, Francesca Reale, Luisa Romano, Giovanni Tallini, Giovanni Zelano, Alfredo Pontecorvi. (2001) Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type. Cancer 92:9, 2273-2279
CrossRef99
Richard J. Robbins, R. Michael Tuttle, Martin Sonenberg, Ashok Shaha, Renu Sharaf, Heather Robbins, Martin Fleisher, Steven M. Larson. (2001) Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin. Thyroid 11:9, 865-869
CrossRef100
Javier I. Torréns, Henry B. Burch. (2001) SERUM THYROGLOBULIN MEASUREMENT. Endocrinology & Metabolism Clinics of North America 30:2, 429-467
CrossRef101
Bryan R. Haugen, Eugene C. Lin. (2001) ISOTOPE IMAGING FOR METASTATIC THYROID CANCER. Endocrinology & Metabolism Clinics of North America 30:2, 469-492
CrossRef102
I. R. MCDOUGALL, J. DAVIDSON, G. M. SEGALL. (2001) Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nuclear Medicine Communications 22:5, 485-492
CrossRef103
SALIL SARKAR, MENES AFRIYIE, CHRISTOPHER PALESTRO. (2001) Clinical Nuclear Medicine 26:5, 392-395
CrossRef104
K vanTol. (2001) Differentiated thyroid carcinoma in the elderly. Critical Reviews in Oncology/Hematology 38:1, 79-91
CrossRef105
J.D. Safer, S.D. Colan, L.M. Fraser, F.E. Wondisford. (2001) A Pituitary Tumor in a Patient with Thyroid Hormone Resistance: A Diagnostic Dilemma. Thyroid 11:3, 281-291
CrossRef106
I. Ross McDougall, Ronald J. Weigel. (2001) Recombinant human thyrotropin in the management of thyroid cancer. Current Opinion in Oncology 13:1, 39-43
CrossRef107
I. Bofilias, U. Hess. 2000. , 450-462.
CrossRef108
Regional Thyroid Cancer Group. (2000) Northern Cancer Network Guidelines for Management of Thyroid Cancer. Clinical Oncology 12:6, 373-391
CrossRef109
Ernest L. Mazzaferri, Richard T. Kloos. (2000) Using Recombinant Human TSH in the Management of Well-Differentiated Thyroid Cancer: Current Strategies and Future Directions. Thyroid 10:9, 767-778
CrossRef110
Osamah Alsanea. (2000) Familial nonmedullary thyroid cancer. Current Treatment Options in Oncology 1:4, 345-351
CrossRef111
T. Paterakis, H. Ebels, U.K. Mallick, G. Proud, N. Jones, T. Lennard, H. Lucraft, J. Fenwick, D. Weightman, P. Kendall-Taylor, P. Perros. (2000) Lack of Antigenicity of Recombinant Human Thyrotropin After Multiple Injections in Patients with Differentiated Thyroid Cancer. Thyroid 10:7, 623-623
CrossRef112
J. M. DURSKI, R. J. WEIGEL, I. R McDOUGALL. (2000) Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nuclear Medicine Communications 21:6, 521-528
CrossRef113
Douglas S. Tyler, Ashok R. Shaha, Robert A. Udelsman, Steven I. Sherman, Norman W. Thompson, Jeffrey F. Moley, Douglas B. Evans. (2000) Thyroid Cancer: 1999 Update and Evaluation of Solitary Thyroid Nodules. Annals of Surgical Oncology 7:5, 376-398
CrossRef114
KATHLEEN M. COLLERAN, MARK R. BURGE. (1999) Isolated Thyrotropin Deficiency Secondary to Primary Empty Sella in a Patient with Differentiated Thyroid Carcinoma: An Indication for Recombinant Thyrotropin. Thyroid 9:12, 1249-1252
CrossRef115
JÖRN H. RISSE, FRANK GRÜNWALD, HANS BENDER, HEINRICH SCHÜLLER, DIRK VAN ROOST, HANS-JÜRGEN BIERSACK. (1999) Recombinant Human Thyrotropin in Thyroid Cancer and Hypopituitarism Due to Sella Metastasis. Thyroid 9:12, 1253-1256
CrossRef116
URSZULA S. MASIUKIEWICZ, INAAM A. NAKCHBANDI, ANDREW F. STEWART, SILVIO E. INZUCCHI. (1999) Papillary Thyroid Carcinoma Metastatic to the Pituitary Gland. Thyroid 9:10, 1023-1027
CrossRef117
C. Nutting, S. Hyer, L. Vini, C. Harmer. (1999) Failure of TSH Rise Prior to Radio-Iodine Therapy for Thyroid Cancer: Implications for Treatment. Clinical Oncology 11:4, 269-271
CrossRef118
Mete Duren, Allan E Siperstein, Wen Shen, Quan-Yang Duh, Eugene Morita, Orlo H Clark. (1999) Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 126:1, 13-19
CrossRef119
PAUL W. LADENSON. (1999) Strategies for Thyrotropin Use to Monitor Patients with Treated Thyroid Carcinoma. Thyroid 9:5, 429-433
CrossRef120
BRUCE D. WEINTRAUB, MARIUSZ W. SZKUDLINSKI. (1999) Development and In Vitro Characterization of Human Recombinant Thyrotropin. Thyroid 9:5, 447-450
CrossRef121
Edwin L Kaplan. (1999) Endocrine surgery. Journal of the American College of Surgeons 188:2, 118-126
CrossRef122
Steven I. Sherman. (1999) Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Seminars in Surgical Oncology 16:1, 30-33
CrossRef123
Ian D. Hay, Clive S. Grant, Erik J. Bergstralh, Geoffrey B. Thompson, Jon A. van Heerden, John R. Goellner. (1998) Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?. Surgery 124:6, 958-966
CrossRef124
Steven I. Sherman. (1998) Staging of thyroid carcinoma-reply. Cancer 83:5, 848-850
CrossRef125
Schlumberger, Martin Jean, . (1998) Papillary and Follicular Thyroid Carcinoma. New England Journal of Medicine 338:5, 297-306
Full Text126
Utiger, Robert D., . (1997) Follow-up of Patients with Thyroid Carcinoma. New England Journal of Medicine 337:13, 928-931
Full Text
